How can we use our growing understanding of gene transcription to discover effective new medicines?

Current Opinion in Biotechnology

Volumn 8, Issue 6, 1997, Pages 713-717

  Latchman, David S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR;

DRUG DEVELOPMENT; DRUG TARGETING; GENETIC TRANSCRIPTION; HORMONE RESPONSE; INFLAMMATION; PRIORITY JOURNAL; REVIEW;

EID: 0030686461     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(97)80125-5     Document Type: Article

References (38)

1. Latchman DS. 3 Gene Regulation. 1998;Chapman and Hall, London.
2. Cai W, Hu L, Foulkes JG. Transcription-modulating drugs: mechanism and selectivity. of special interest Curr Opin Biotechnol. 7:1996;608-615 A comprehensive review of the currently used drugs that modulate transcription and their mechanism of action.
3. Delrosaro M, Stephas JC, Zakel J, Escobedo J, Giese K. Positive selection system to screen for inhibitors of human immunodeficiency virus-1 transcription. Nat Biotechnol. 14:1996;1592-1596.
4. Shiau SP, Glasebrook A, Hardikar SD, Yang NN, Hershberger CL. Activation of the human estrogen receptor by estrogenic and anti-estrogenic compounds in Saccharomyces cerevisiae: a positive selection system. Gene. 179:1996;205-210.
5. Latchman DS. 2 Eukaryotic transcription factors. 1995;Academic Press, London, San Diego.
6. Latchman DS. Transcription factor mutations and human disease. N Engl J Med. 334:1996;28-33.
7. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 14:1996;376-387.
8. Neurath MF, Pettersson S, Zumbuschenfelde KHM, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. of outstanding interest Nat Med. 9:1996;998-1004 The authors show that local administration of antisense oligonucleotides to NFκB in vivo is an effective treatment in two different models of colitis. Thus, opening up the possibility of using antisense oligonucleotides against a transcription factor therapeutically in vivo.
9. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. of outstanding interest Nat Med. 2:1996;985-991 This study shows that delivery of p53 in patients with human non-small lung cancer has no toxic effects for up to five months. Most importantly, tumour regression was noted in three patients and tumour growth stabilized in three other patients.
10. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. Cell. 83:1995;835-839.
11. Fan JD, Wagner BL, McDonnell DP. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. Mol Endocrinol. 10:1996;1605-1616.
12. Gallo MA, Kaufman D. Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin Oncol. 24:1997;71-80. (suppl 1).
13. Wurtz J-M, Bourguet W, Renaud J-P, Vivat V, Chambon P, Moras D, Gronemeyer H. A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol. 3:1996;87-94.
14. Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr Opin Cell Biol. 9:1997;222-232.
15. L'Horset F, Dauvois S, Heery DM, Cavaillès V, Parker MG. RIP-140 interacts with multiple nuclear receptors by means of two distinct sites. Mol Cell Biol. 16:1996;6029-6036.
16. Treisman R. Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol. 8:1996;205-215.
17. Shibasaki F, Price ER, Milan D, McKeon F. Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4. of special interest Nature. 382:1996;370-373 The authors demonstrate that calcineurin-mediated dephosphorylation of the nuclear factor of activated T cells (NF-AT) unmasks a nuclear localization signal on NF-AT which then moves into the nucleus and activates transcription. This provides insights into the mechanism of NF-AT activation, which could be targetted therapeutically.
18. Beals CR, Clipstone NA, Ho SN, Crabtree GR. Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. Genes Dev. 11:1997;824-834.
19. James DG. A new immunosuppressant: tracrolinus. Postgrad Med J. 72:1996;852-856.
20. Pierce JW, Read Ma, Ding H, Luscinskas FW, Collins T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol. 156:1996;3961-3969.
21. Baeurale PA, Baltimore D. NFκB ten years after. Cell. 87:1996;13-20.
22. Mosieniak G, Figiel I, Kaminska B. Cyclosporin A, an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor. J Neurochem. 68:1997;1142-1149.
23. Su Q, Eugster HP, Ryffel B, Dumont FJ. Cyclosporin A enhances the calcium-dependent induction of AP-1 complex and c-fos mRNA in a T cell lymphoma. Biochem Biophys Res Commun. 229:1996;249-256.
24. Muraoka K, Fujimoto K, Sun X, Yoshioka K, Shimizu K, Yagi M, Bose H Jr, Miyazaki I, Yamamoto K. Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy. J Clin Inv. 97:1996;2433-2439.
25. Greenblatt J. RNA polymerase II holoenzyme and transcriptional regulation. Curr Opin Cell Biol. 9:1997;310-319.
26. Haigh A, Greaves R, O'Hare P. Interference with the assembly of a virus-host transcription complex by peptide competition. Nature. 344:1990;257-259.
27. Bandara LR, Girling R, La Thangue NG. Apoptosis induced in mammalian cells by small peptides and functionally antagonize the Rb-regulated E2F transcription factor. of special interest Nat Biotechnol. 15:1997;896-901 A peptide that disrupts the heterodimerization of the E2F and DP-1 transcription factors prevents DNA binding of E2F in cell extracts and intact cells. Furthermore, when added to intact tumour cells, this peptide prevents the anti-apoptotic effect of E2F and, hence, induces death of the tumour cells.
28. Kauvar LM. Peptide mimetic drugs: a comment on progress and prospects. Nat Biotechnol. 14:1996;709.
29. Cozens R, Mestan J, Poncioni B, Rosel J, Tintelnothomley M, Lang M. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability. J Med Chem. 39:1996;3203-3216.
30. Ghosh AK, Kincaid JF, Walters DE, Chen Y, Chaudhuri NC, Thompson WJ, Culberson C, Fitzgerald PMD, Lee HY, Mckee SP, et al. Nonpeptidal P-2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation. J Med Chem. 39:1996;3278-3290.
31. Hong L, Treharne A, Hartsuck JA, Foundling S, Tang J. Crystal structures of complexes of peptidic inhibitor with wild-type and two mutant HIV-1 proteases. Biochemistry. 35:1996;10627-10633.
32. Bailly C, Brana M, Waring MJ. Sequence-selective intercalation of antitumour bis-naphthalmides into DNA - evidence for an approach via the major groove. Eur J Biochem. 240:1996;195-208.
33. Gao YG, Priebe W, Wang AHJ. Substitutions at C2 of daunosamine in the anticancer drug daunorubicin alter its DNA-binding sequence specificity. Eur J Biochem. 240:1996;331-335.
34. Kumr RA, Ikemoto N, Patel DJ. Solution structure of the esperamicin A(1)-DNA complex. J Mol Biol. 265:1997;173-186.
35. Kumar RA, Ikemoto N, Patel DJ. Solution structure of the calicheamicin gamma (I)(I)-DNA complex. J Mol Biol. 265:1997;187-201.
36. Lavrosky Y, Stoltz RA, Vlassov VV, Abraham NG. c-fos protooncogene transcription can be modulated by oligonucleotide-mediated formation of triplex structures in vitro. Eur J Biochem. 238:1996;582-590.
37. Aggarwal BB, Schwarz L, Hogan ME, Rando RF. Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human gliobastoma tumor cells. of special interest Cancer Res. 56:1996;5156-5164 Four different triple helix forming oligonucleotides targeted to different transcription factor binding sites in the TNF gene promoter inhibit both TNF production and TNF-dependent growth of tumour cells.
38. Durang M, Maurizot JC. Distamycin A complexation with a nucleic acid triple helix. Biochemistry. 35:1996;9133-9139.